Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 407

1.

Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.

Blackmer AB, Oertel MD, Valgus JM.

Ann Pharmacother. 2009 Oct;43(10):1636-46. doi: 10.1345/aph.1M136. Epub 2009 Sep 8. Review.

PMID:
19737996
2.

Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.

Efird LE, Kockler DR.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1383-7. Epub 2006 Jun 20. Review.

PMID:
16788093
3.

Fondaparinux as a treatment option for heparin-induced thrombocytopenia.

Papadopoulos S, Flynn JD, Lewis DA.

Pharmacotherapy. 2007 Jun;27(6):921-6. Review.

PMID:
17542773
4.

Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.

Lobo B, Finch C, Howard A, Minhas S.

Thromb Haemost. 2008 Jan;99(1):208-14. doi: 10.1160/TH07-04-0252.

PMID:
18217156
5.

Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.

Dager WE, Andersen J, Nutescu E.

Pharmacotherapy. 2004 Jul;24(7 Pt 2):88S-94S. Review.

PMID:
15317404
6.

Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?

Badger NO.

J Pharm Pract. 2010 Jun;23(3):235-8. doi: 10.1177/0897190010362170. Epub 2010 Apr 13. Review.

PMID:
21507819
7.

Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.

Wester JP, Leyte A, Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Haak EA, Porcelijn L, Zandstra DF.

Neth J Med. 2007 Mar;65(3):101-8.

8.

[Management of heparin-induced thrombocytopenia].

Aouizerate P, Guizard M.

Therapie. 2002 Nov-Dec;57(6):577-88. Review. French.

PMID:
12666266
9.

Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series.

Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW.

J Thromb Haemost. 2011 Dec;9(12):2389-96. doi: 10.1111/j.1538-7836.2011.04487.x.

10.

Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.

Grouzi E, Kyriakou E, Panagou I, Spiliotopoulou I.

Clin Appl Thromb Hemost. 2010 Dec;16(6):663-7. doi: 10.1177/1076029609347900. Epub 2009 Oct 13.

PMID:
19825921
11.

Fondaparinux-associated heparin-induced thrombocytopenia.

Bhatt VR, Aryal MR, Shrestha R, Armitage JO.

Eur J Haematol. 2013 Nov;91(5):437-41. doi: 10.1111/ejh.12179. Epub 2013 Aug 20.

PMID:
23905719
12.

Heparin-induced thrombocytopenia and recent advances in its therapy.

Hassan Y, Awaisu A, Aziz NA, Aziz NH, Ismail O.

J Clin Pharm Ther. 2007 Dec;32(6):535-44. Review.

PMID:
18021330
13.

Pharmacotherapy of heparin- induced thrombocytopenia.

Dager WE, White RH.

Expert Opin Pharmacother. 2003 Jun;4(6):919-40. Review.

PMID:
12783589
14.

Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.

Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Kropff S, Müller MM, Lindhoff-Last E.

Thromb Res. 2014 Jul;134(1):29-35. doi: 10.1016/j.thromres.2014.03.029. Epub 2014 Mar 18.

PMID:
24703295
15.

Fondaparinux: does it cause HIT? Can it treat HIT?

Warkentin TE.

Expert Rev Hematol. 2010 Oct;3(5):567-81. doi: 10.1586/ehm.10.54. Review.

PMID:
21083474
16.

Treatment of heparin-induced thrombocytopenia with fondaparinux.

Harenberg J, Jörg I, Fenyvesi T.

Haematologica. 2004 Aug;89(8):1017-8.

17.

Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience.

Schindewolf M, Scheuermann J, Kroll H, Marzi I, Kaufmann R, Boehncke WH, Ludwig RJ, Lindhoff-Last E.

Thromb Res. 2012 Jan;129(1):17-21. doi: 10.1016/j.thromres.2011.06.008. Epub 2011 Jul 7.

PMID:
21741076
18.

A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients.

Benken ST, Tillman N, Dajani S, Shah A, Thomas T.

J Cardiothorac Surg. 2014 Mar 21;9:55. doi: 10.1186/1749-8090-9-55.

19.

The HIT treatment in a cardiac surgery patient.

Anna N, Boyan T, Kader MA, Catherine M, Matthias K.

Int J Cardiol. 2010 Oct 29;144(3):405-7. doi: 10.1016/j.ijcard.2009.03.027. Epub 2009 Mar 26.

PMID:
19324432
20.

Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.

Alsaleh KA, Al-Nasser SM, Bates SM, Patel A, Warkentin TE, Arnold DM.

Am J Hematol. 2008 Nov;83(11):876-8. doi: 10.1002/ajh.21273.

Supplemental Content

Support Center